receives

Girl With Deadly Brain Cancer Glioblastoma Multiforme Receives Heartwarming …
Ellie is diagnosed with glioblastoma multiforme, characterized by a fast-growing brain tumor. There is a 25 percent chance of a child surviving five years after initial diagnosis, according to the American Brain Tumor Association. Radiation and ... [...]
1
Like
Save
ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS …
We have obtained encouraging preclinical data in melanoma and prostate cancer to support the continued advancement of our immunotherapy program and this important addition to our intellectual property estate provides potential protection for our ... [...]
2
Like
Save
Breast Cancer at DHR receives accreditation design
Through our affiliations with University of Texas Health Science Center and the Cancer Therapy Research Center, the Breast Center at DHR has been able to treat over 250 analytic breast cancer cases in one year. Providing both inpatient and outpatient ... [...]
5
Like
Save
Patent Profile: VM Institute of Research Receives Patent for Method of …
The '270 patent, which is assigned to the VM Institute of Research (Montreal, Canada), contains claims to a method of treating breast cancer in a subject having triple negative breast cancer. For some time doctors and scientists hypothesized that the ... [...]
6
Like
Save
Advanced Breast Cancer Treatment Halaven® (eribulin) Receives Reimbursement in …
Halaven® (eribulin), a first-in-class treatment for women with locally advanced or metastatic breast cancer who have progressed after at least one prior chemotherapeutic regimen for advanced disease, has received reimbursement by the health authorities ... [...]
3
Like
Save
Samsung Bioepis receives European approval for Enbrel biosimilar to treat RA
Samsung Bioepis Co., Ltd, a biopharmaceutical company, announced the European Commission's (EC) approval of Benepali – a biosimilar referencing Enbrel (etanercept), also known as SB4 – for the treatment of rheumatoid arthritis, psoriatic arthritis ... [...]
5
Like
Save
Novartis receives FDA nod for ankylosing spondylitis and psoriatic arthritis drug
Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of two new indications - adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both ... [...]
3
Like
Save